Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A combination of two targeted therapies led to long-lasting remission in a small study of patients with hairy cell leukemia.
Sonia Dolinger runs a meal delivery business and fundraises for cancer research. She has chronic lymphocytic leukemia.
Several new medications for kidney cancer have been approved in recent years.
PARP inhibitor reduces the risk of disease recurrence in BRCA-positive people with high-risk early breast cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
New targeted therapy shrank tumors in nearly a quarter of patients with bile duct cancer.
Rybrevant is the first treatment for people with advanced non-small-cell lung cancer whose tumors have EGFR exon 20 insertion mutations.
The new findings are an important first step in moving toward using even less radiation to treat high-risk pediatric Hodgkin lymphoma.
Zynlonta led to complete remission in nearly a quarter of patients with large B-cell lymphoma.
The antibody-drug conjugate shrank tumors in 28% of people with locally advanced or metastatic urothelial cancer.
The monoclonal antibody reduces the risk of disease progression or death by 45%.
The response rate was nearly 50% for people with breast, colon, pancreatic and other cancers.
The antibody-drug conjugate is the second drug approved for metastatic breast cancer in the course of a week.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.